Olivier Tournilhac
Papers
1
Total Citations
16
H-Index
1
About
Dr. Olivier Tournilhac is a distinguished hematologist and researcher whose work focuses on the intricate interplay between chronic myeloid leukemia (CML) and other myeloproliferative neoplasms (MPNs). His most impactful contribution is a seminal 2009 study, cited 16 times, which uncovered a critical diagnostic nuance: a thrombocytosis emerging in Philadelphia-positive CML patients achieving molecular response to imatinib can signal an underlying JAK2V617F-positive MPN. This finding has profound clinical implications, highlighting the need for vigilant monitoring when treatment responses deviate from expected patterns. By elucidating this dual-pathology phenomenon, Dr. Tournilhac advanced the understanding of clonal hematopoiesis and the complexities of targeted therapy. His work has influenced hematology practice, particularly in distinguishing treatment-related effects from concurrent MPNs. For students and researchers, his study serves as a cautionary tale about the limitations of single-pathway targeting and the importance of comprehensive molecular diagnostics in managing hematologic malignancies.
Research Focus
Key Achievements
Top Papers
- 1